Alcresta develops rare disease, enzyme-based products helping to address fat malabsorption in patients who are enterally fed at home or in the hospital. Our RELiZORB® (immobilized lipase) is indicated for use in pediatric patients (ages 1+) and adult patients to hydrolyze fats in enteral formula. Please see Instructions for Use at wwww.relizorb.com.
Alcresta Therapeutics, Inc.
Alcresta Therapuetics
130 Turner St
Building 3 Suite 200
Waltham, MA 02453
